Propel Bio Management, LLC

CIK 0001969764 · LOS ANGELES, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source

Propel Bio Management, LLC reported 29 positions worth $191.1M as of June 30, 2026 (13F filed August 13, 2026). Largest holding: PAGP (16.2%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$191.1M
2026 Q2
Positions
29
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
68.1%
Est. Net Flow (Q)
2026 Q2
10 / 29 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1PAGPPLAINS GP HOLDINGS LP-CLSH$30.9M16.16%1,272,360
2ACHVACHIEVE LIFE SCIENCES INCSH$26.3M13.79%4,034,018
3CORTCORCEPT THERAPEUTICS INCSH$11.9M6.21%136,499
4PHATPHATHOM PHARMACEUTICALS ISH$11.4M5.96%1,050,358
5DCTHDELCATH SYSTEMS INCSH$11.0M5.74%871,460
6MISTMILESTONE PHARMACEUTICALSSH$10.0M5.21%7,429,590
7CMPSCOMPASS PATHWAYS PLCSH$8.1M4.24%573,086
8KYTXKYVERNA THERAPEUTICS INCSH$7.9M4.12%883,198
9ARTVARTIVA BIOTHERAPEUTICS INSH$6.8M3.54%696,436
10ABEOABEONA THERAPEUTICS INCSH$6.1M3.18%983,070

The free plan shows the top 10 positions. The remaining 19 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Propel Bio Management, LLC hold as of Q2 2026?

Propel Bio Management, LLC reported 29 positions worth $191.1M in its Q2 2026 13F filing. Largest positions: PAGP (16.2%), ACHV (13.8%), CORT (6.2%), PHAT (6.0%) and DCTH (5.7%).

What did Propel Bio Management, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Propel Bio Management, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.